Physician profile
John J Moy
NPI 1700804853
$2,914.13
in general payments reported to CMS, 2019-2025
24 companies · $334 in 2025
The $334 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $62.76 · 2021: $118 · 2022: $1,031 · 2023: $656 · 2024: $372 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,362.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $883.46 | 2022 | |
| Alcon Vision LLC | $284.01 | 2021-2025 | Rocklatan, Clareon, Hydrus Microstent |
| Mallinckrodt Hospital Products INC. | $216.33 | 2023-2024 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $170.46 | 2019 | |
| Horizon Therapeutics Plc | $134.87 | 2023 | Tepezza |
| Biotissue Holdings INC. | $131.75 | 2021-2023 | |
| Amgen INC. | $130.14 | 2024-2025 | Tepezza |
| Abbvie INC. | $129.82 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $109.04 | 2019-2022 | |
| Allergan, INC. | $108.64 | 2019 | |
| Oyster Point Pharma, INC. | $106.41 | 2023 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $97.00 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $78.65 | 2020-2021 | |
| Rxsight INC | $60.45 | 2022-2025 | Light Adjustable Lens (Lal), Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Harrow Eye, LLC | $58.78 | 2024-2025 | Vevye |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $41.65 | 2023-2024 | Iyuzeh |
| Johnson & Johnson Surgical Vision, INC. | $28.77 | 2019 | |
| Sun Pharmaceutical Industries INC. | $27.91 | 2023 | Cequa |
| Bausch & Lomb Americas INC. | $24.98 | 2023 | Vyzulta |
| Sight Sciences, INC. | $23.68 | 2022 | |
| New World Medical,INC. | $20.65 | 2025 | Via360, Clearpath, Streamline |
| Tearlab Corp | $18.70 | 2023 | Tearlab Osmolarity System |
| Dompe US, INC. | $14.88 | 2022 | |
| Shire North American Group INC | $13.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Moy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.